Furthermore, some studies suggest that CaSR could modulate both the intestinal inflammation and barrier function, which are key features of IBD; for example, Elajnaf et al. found out that the activation of CaSR by its agonist cinacalcet reduced inflammation and improved barrier function in a mouse model of colitis [46]. The gene discussed is CASR; the disease is colitis.